Terms: = Lymphoma AND uPA AND Treatment
15 results:
1. Impaired fibrinolysis and increased clot strength are potential risk factors for thrombosis in lymphoma.
Bønløkke ST; Fenger-Eriksen C; Ommen HB; Hvas AM
Blood Adv; 2023 Nov; 7(22):7056-7066. PubMed ID: 37756519
[TBL] [Abstract] [Full Text] [Related]
2. Amentoflavone Induces Apoptosis and Reduces Expression of Anti-apoptotic and Metastasis-associated Proteins in Bladder Cancer.
Chiang CH; Yeh CY; Chung JG; Chiang IT; Hsu FT
Anticancer Res; 2019 Jul; 39(7):3641-3649. PubMed ID: 31262890
[TBL] [Abstract] [Full Text] [Related]
3. Progesterone Receptor Isoforms, Nuclear Corepressor-1 and Steroid Receptor Coactivator-1 and B-Cell lymphoma 2 and Akt and Akt Phosphorylation Status in Uterine Myomas after Ulipristal Acetate treatment: A Systematic Immunohistochemical Evaluation.
Courtoy GE; Donnez J; Marbaix E; Barreira M; Luyckx M; Dolmans MM
Gynecol Obstet Invest; 2018; 83(5):443-454. PubMed ID: 29227976
[TBL] [Abstract] [Full Text] [Related]
4. Amurubicinol-induced eotaxin-3 expression in human NCI-H69 small cell lung carcinoma cells.
Niiya M; Niiya K; Shibakura M; Asaumi N; Yoshida C; Tanimoto M
Oncol Rep; 2006 Mar; 15(3):571-6. PubMed ID: 16465414
[TBL] [Abstract] [Full Text] [Related]
5. Involvement of ERK1/2 and p38 MAP kinase in doxorubicin-induced upa expression in human RC-K8 lymphoma and NCI-H69 small cell lung carcinoma cells.
Niiya M; Niiya K; Shibakura M; Asaumi N; Yoshida C; Shinagawa K; Teshima T; Ishimaru F; Ikeda K; Tanimoto M
Oncology; 2004; 67(3-4):310-9. PubMed ID: 15557793
[TBL] [Abstract] [Full Text] [Related]
6. Camptothecin induces urokinase-type plasminogen activator gene-expression in human RC-K8 malignant lymphoma and H69 small cell lung cancer cells.
Shibakura M; Niiya K; Kiguchi T; Nakata Y; Tanimoto M
Acta Med Okayama; 2002 Oct; 56(5):223-7. PubMed ID: 12530505
[TBL] [Abstract] [Full Text] [Related]
7. The diphtheria toxin/urokinase fusion protein (DTAT) is selectively toxic to CD87 expressing leukemic cells.
Ramage JG; Vallera DA; Black JH; Aplan PD; Kees UR; Frankel AE
Leuk Res; 2003 Jan; 27(1):79-84. PubMed ID: 12479856
[TBL] [Abstract] [Full Text] [Related]
8. Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy.
Mustjoki S; Sidenius N; Sier CF; Blasi F; Elonen E; Alitalo R; Vaheri A
Cancer Res; 2000 Dec; 60(24):7126-32. PubMed ID: 11156421
[TBL] [Abstract] [Full Text] [Related]
9. The novel anti-tumour agent oxamflatin differentially regulates urokinase and plasminogen activator inhibitor type 2 expression and inhibits urokinase-mediated proteolytic activity.
Dear AE; Medcalf RL
Biochim Biophys Acta; 2000 Jun; 1492(1):15-22. PubMed ID: 11004477
[TBL] [Abstract] [Full Text] [Related]
10. Urokinase-mediated transactivation of the plasminogen activator inhibitor type 2 (PAI-2) gene promoter in HT-1080 cells utilises AP-1 binding sites and potentiates phorbol ester-mediated induction of endogenous PAI-2 mRNA.
Dear AE; Costa M; Medcalf RL
FEBS Lett; 1997 Feb; 402(2-3):265-72. PubMed ID: 9037208
[TBL] [Abstract] [Full Text] [Related]
11. Inhibitory effect of a synthetic prostacyclin analogue, beraprost, on urokinase-type plasminogen activator expression in RC-K8 human lymphoma cells.
Nomura N; Niiya K; Shinbo M; Ozawa T; Hayakawa Y; Higashiyama K; Fujimaki M; Sakuragawa N
Thromb Haemost; 1996 Jun; 75(6):928-32. PubMed ID: 8822588
[TBL] [Abstract] [Full Text] [Related]
12. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain.
Høyer-Hansen G; Rønne E; Solberg H; Behrendt N; Ploug M; Lund LR; Ellis V; Danø K
J Biol Chem; 1992 Sep; 267(25):18224-9. PubMed ID: 1381366
[TBL] [Abstract] [Full Text] [Related]
13. Localization of urokinase-type plasminogen activator receptor on U937 cells: phorbol ester PMA induces heterogeneity.
Hansen SH; Behrendt N; Danø K; Kristensen P
Exp Cell Res; 1990 Apr; 187(2):255-62. PubMed ID: 2156717
[TBL] [Abstract] [Full Text] [Related]
14. Phorbol ester induces the biosynthesis of glycosylated and nonglycosylated plasminogen activator inhibitor 2 in high excess over urokinase-type plasminogen activator in human U-937 lymphoma cells.
Genton C; Kruithof EK; Schleuning WD
J Cell Biol; 1987 Mar; 104(3):705-12. PubMed ID: 3102504
[TBL] [Abstract] [Full Text] [Related]
15. Plasminogen activator-specific inhibitors produced by human monocytes/macrophages.
Wohlwend A; Belin D; Vassalli JD
J Exp Med; 1987 Feb; 165(2):320-39. PubMed ID: 2434595
[TBL] [Abstract] [Full Text] [Related]
